Savannah Demko

CHICAGO — Using AI in rheumatology was an important discussion topic at ACR Convergence 2025, according to Micaela F. Bayard, MD.

Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type

CHICAGO — Several presentations from ACR Convergence 2025 focused on how rheumatologists can use digital tools to engage underrepresented populations, according to Micaela F. Bayard , MD.

CHICAGO — In this Healio video interview, Micaela F. Bayard, MD, discussed women’s health and reproductive health outcomes in rheumatic diseases, two topics that were featured at ACR Convergence 2025.

CHICAGO — Vagus nerve-mediated neuroimmune modulation by electrical stimulation using an implantable device was well-tolerated and had durable efficacy through 12-months in adults with rheumatoid arthritis, according to results from the RESET-RA study presented at ACR Convergence 2025.

CHICAGO — Citrullinated protein-targeted chimeric antigen receptor regulatory T cells showed a promising safety profile in highly refractory patients with rheumatoid arthritis, according to phase 1 data presented at ACR Convergence 2025. This novel therapy known as SBT777101, an autologous regulatory T-cell (Treg) product transduced with a CAR specific for citrullinated proteins, also

CHICAGO — Neuroimmune modulation inhibited progression of structural damage in patients with rheumatoid arthritis who had inadequate response or intolerance to DMARD therapy, according to data presented at ACR Convergence 2025.

CHICAGO — Neuroimmune modulation could be an “emerging therapeutic approach” for patients with rheumatoid arthritis who had incomplete response or intolerance to anti-TNF therapy, according to Minna Kohler, MD, RhMSUS.